209 related articles for article (PubMed ID: 36038710)
1. The Potential Value-Based Price of a Multi-Cancer Early Detection Genomic Blood Test to Complement Current Single Cancer Screening in the USA.
Tafazzoli A; Ramsey SD; Shaul A; Chavan A; Ye W; Kansal AR; Ofman J; Fendrick AM
Pharmacoeconomics; 2022 Nov; 40(11):1107-1117. PubMed ID: 36038710
[TBL] [Abstract][Full Text] [Related]
2. An Exploratory Analysis of the Cost-Effectiveness of a Multi-cancer Early Detection Blood Test Compared with Standard of Care Screening in Ontario, Canada.
Lewis D; Wong WWL; Lipscomb J; Horton S
Pharmacoeconomics; 2024 Apr; 42(4):393-407. PubMed ID: 38150120
[TBL] [Abstract][Full Text] [Related]
3. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
[TBL] [Abstract][Full Text] [Related]
4. Estimating the population health impact of a multi-cancer early detection genomic blood test to complement existing screening in the US and UK.
Hackshaw A; Cohen SS; Reichert H; Kansal AR; Chung KC; Ofman JJ
Br J Cancer; 2021 Nov; 125(10):1432-1442. PubMed ID: 34426664
[TBL] [Abstract][Full Text] [Related]
5. Multi-cancer early detection test in symptomatic patients referred for cancer investigation in England and Wales (SYMPLIFY): a large-scale, observational cohort study.
Nicholson BD; Oke J; Virdee PS; Harris DA; O'Doherty C; Park JE; Hamady Z; Sehgal V; Millar A; Medley L; Tonner S; Vargova M; Engonidou L; Riahi K; Luan Y; Hiom S; Kumar H; Nandani H; Kurtzman KN; Yu LM; Freestone C; Pearson S; Hobbs FR; Perera R; Middleton MR
Lancet Oncol; 2023 Jul; 24(7):733-743. PubMed ID: 37352875
[TBL] [Abstract][Full Text] [Related]
6. Projecting the Impact of Multi-Cancer Early Detection on Late-Stage Incidence Using Multi-State Disease Modeling.
Lange JM; Gogebakan KC; Gulati R; Etzioni R
Cancer Epidemiol Biomarkers Prev; 2024 Jun; 33(6):830-837. PubMed ID: 38506751
[TBL] [Abstract][Full Text] [Related]
7. Patient Preferences for Multi-Cancer Early Detection (MCED) Screening Tests.
Gelhorn H; Ross MM; Kansal AR; Fung ET; Seiden MV; Krucien N; Chung KC
Patient; 2023 Jan; 16(1):43-56. PubMed ID: 35844011
[TBL] [Abstract][Full Text] [Related]
8. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set.
Klein EA; Richards D; Cohn A; Tummala M; Lapham R; Cosgrove D; Chung G; Clement J; Gao J; Hunkapiller N; Jamshidi A; Kurtzman KN; Seiden MV; Swanton C; Liu MC
Ann Oncol; 2021 Sep; 32(9):1167-1177. PubMed ID: 34176681
[TBL] [Abstract][Full Text] [Related]
9. Evaluating the impact of multicancer early detection testing on health and economic outcomes: Toward a decision modeling strategy.
Lipscomb J; Horton S; Kuo A; Tomasetti C
Cancer; 2022 Feb; 128 Suppl 4():892-908. PubMed ID: 35133662
[TBL] [Abstract][Full Text] [Related]
10. Impact of screening participation on modelled mortality benefits of a multi-cancer early detection test by socioeconomic group in England.
Smittenaar R; Quaife SL; von Wagner C; Higgins T; Hubbell E; Lee L
J Epidemiol Community Health; 2024 May; 78(6):345-353. PubMed ID: 38429085
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Significance of Blood-Based Multi-cancer Detection in Plasma Cell-Free DNA.
Chen X; Dong Z; Hubbell E; Kurtzman KN; Oxnard GR; Venn O; Melton C; Clarke CA; Shaknovich R; Ma T; Meixiong G; Seiden MV; Klein EA; Fung ET; Liu MC
Clin Cancer Res; 2021 Aug; 27(15):4221-4229. PubMed ID: 34088722
[TBL] [Abstract][Full Text] [Related]
12. Attitudes to multi-cancer early detection (MCED) blood tests for population-based screening: A qualitative study in Great Britain.
Schmeising-Barnes N; Waller J; Marlow LAV
Soc Sci Med; 2024 Apr; 347():116762. PubMed ID: 38520825
[TBL] [Abstract][Full Text] [Related]
13. Modelled mortality benefits of multi-cancer early detection screening in England.
Sasieni P; Smittenaar R; Hubbell E; Broggio J; Neal RD; Swanton C
Br J Cancer; 2023 Jul; 129(1):72-80. PubMed ID: 37185463
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness and budget impact analyses of colorectal cancer screenings in a low- and middle-income country: example from Thailand.
Phisalprapa P; Supakankunti S; Chaiyakunapruk N
J Med Econ; 2019 Dec; 22(12):1351-1361. PubMed ID: 31560247
[No Abstract] [Full Text] [Related]
15. Modeled Reductions in Late-stage Cancer with a Multi-Cancer Early Detection Test.
Hubbell E; Clarke CA; Aravanis AM; Berg CD
Cancer Epidemiol Biomarkers Prev; 2021 Mar; 30(3):460-468. PubMed ID: 33328254
[TBL] [Abstract][Full Text] [Related]
16. Modeled residual current cancer risk after clinical investigation of a positive multicancer early detection test result.
Hudnut AG; Hubbell E; Venn O; Church TR
Cancer; 2023 Jul; 129(13):2056-2063. PubMed ID: 36943898
[TBL] [Abstract][Full Text] [Related]
17. Multi-year clinical outcomes of cancers diagnosed following detection by a blood-based multi-cancer early detection (MCED) test.
Buchanan AH; Lennon AM; Choudhry OA; Elias PZ; Rego SP; Sadler JR; Roberta J; Zhang Y; Flake DD; Salvati ZM; Wagner ES; Fishman EK; Papadopoulos N; Beer TM
Cancer Prev Res (Phila); 2024 May; ():. PubMed ID: 38819783
[TBL] [Abstract][Full Text] [Related]
18. Clinical performance and utility: A microsimulation model to inform the design of screening trials for a multi-cancer early detection test.
Dai JY; Zhang J; Braun JV; Simon N; Hubbell E; Zhang N
J Med Screen; 2024 Feb; ():9691413241228041. PubMed ID: 38304990
[TBL] [Abstract][Full Text] [Related]
19. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
